대사이상 치료제 시장 : 질환별, 치료별, 투여 경로별, 최종사용자별, 세계 예측(2024-2032년)

Metabolic Disorder Therapeutics Market size will record 7.5% CAGR between 2024 and 2032, led by significant investments in R&D by pharmaceutical and biotechnology companies to foster innovations. To cite an instance, in November 2023, Biolexis Therapeutics, Inc. secured $10 million in funding to advance its metabolic drug development. Rising collaborations between the industry players and academia are also making way for new discoveries and advancements in metabolic disorder therapeutics. The increase in clinical trials is expanding the pipeline of potential treatments for providing new options for patients, further shaping the market growth.

The metabolic disorder therapeutics industry is classified into disease, therapy type, route of administration, end-user, and region.

In terms of disease, the market size from the obesity segment may record a robust CAGR from 2024 to 2032 owing to the advances in pharmacotherapy, surgical techniques, and integrated care models for improving outcomes for patients. The emerging research in genetic and microbiome is also influencing future breakthroughs, making the management of obesity more effective and personalized, subsequently adding to the segment growth.

By end-user, the metabolic disorder therapeutics industry value from the specialty clinics segment will expand through 2032, due to their rising preference for offering specialized, comprehensive, and patient-centered care. Specialty clinics are actively implementing innovative therapies and treatments for metabolic disorders, such as the use of novel pharmacological agents, minimally invasive procedures, and advanced surgical techniques. These clinics also offer chronic care management programs to monitor progress, adjust treatment plans as needed, and address any emerging health issues promptly.

Asia Pacific metabolic disorder therapeutics market size may witness significant CAGR through 2032. This can mainly be ascribed to the increasing burden of metabolic disorders like diabetes, obesity, hyperlipidemia, and metabolic syndrome driven by changing lifestyles, dietary habits and the aging population. The surging government initiatives and public health campaigns are also playing a crucial role in educating the population about metabolic disorders, adding to the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of metabolic disorders
    • 3.2.1.2 Rising R&D activities for developing novel therapeutics
    • 3.2.1.3 Growing awareness and screening programs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost associated with treatment
    • 3.2.2.2 Stringent regulatory requirements
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscap
• 3.6 Pipeline analysis
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Diabetes
• 5.3 Hypercholesterolemia
• 5.4 Lysosomal storage diseases
  • 5.4.1 Gaucher's disease
  • 5.4.2 Metachromatic leukodystrophy
  • 5.4.3 Hurler - Scheie
  • 5.4.4 Sanfilipo A
  • 5.4.5 Other lysosomal storage diseases
• 5.5 Obesity
• 5.6 Inherited metabolic disorders

Chapter 6 Market Estimates and Forecast, By Therapy Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Drug therapy
• 6.3 Enzyme replacement therapy
• 6.4 Substrate reduction therapy
• 6.5 Gene therapy
• 6.6 Small molecule-based therapy
• 6.7 Cellular transplantation

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Specialty clinics
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie, Inc.
• 10.2 Actelion Pharmaceuticals Ltd.
• 10.3 Amgen Inc.
• 10.4 AstraZeneca plc
• 10.5 Biocon Ltd.
• 10.6 BioMarin Pharmaceutical, Inc.
• 10.7 Boehringer Ingelheim GmbH
• 10.8 Bristol-Myers Squibb Company
• 10.9 Cipla, Inc.
• 10.10 CymaBay Therapeutics, Inc.
• 10.11 Eli Lilly and Company
• 10.12 Merck KGaA
• 10.13 Novo Nordisk A/S
• 10.14 Sanofi SA
• 10.15 Shire PLC